间变性淋巴瘤激酶阳性弥漫大B细胞淋巴瘤的研究进展

Research Progress on Anaplastic Lymphoma Kinase-positive Diffuse Large B-cell Lymphoma

间变性淋巴瘤激酶阳性弥漫大B细胞淋巴瘤（anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma, ALK＋DLBCL）是弥漫大B细胞淋巴瘤（DLBCL）的一种罕见的亚型，具有特征性形态学、免疫表型和细胞遗传学特点。其临床过程具侵袭性，预后不良，明确认识该疾病是诊断的关键。选择性ALK抑制剂可能是ALK＋DLBCL患者潜在的治疗选择。

Anaplastic l vmphoma kinase-positive diffuse large B-cell lymphoma （ALK＋ DLBCL） is a rare subtype of DLBCL with characteristic morphologic,immunophenotypic and cytogenetic fea- ture. Most cases follow an aggressive clinical course with a poor prognosis. Recognition is critical to the diagnosis of the disease. Selective ALK inhibitors might provide a potential therapeutic op- tion for patients with this disease.